Russian drug production to decline due to lack of raw material supplies from China

The production of drugs in Russia may decline significantly this year, due to the almost complete suspension of the supplies of raw materials for their production from China, according to recent statements by representatives of some leading drugmakers in Russia and local analysts, reports The Pharma Letter’s local correspondent.

China has traditionally been the largest supplier of active pharmaceutical ingredients (APIs) for the Russian industry.

According to data from the Russian Chamber of Commerce and Industry, currently Russia has enough reserves until April. However, if the situation in China does not stabilize, this could lead to higher prices and even the disappearance of some drugs from the domestic market.